While a few major translational and clinical trials have demonstrated therapeutic potential for SLE by blocking co-stimulation systems involving CTLA-4, B7 and CD40L [44], a major therapeutic breakthrough has yet to be achieved. Here, CD40LG is linked to systemic lupus erythematosus.